Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 12/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17047624 | 0.81 | ALDH3A1 (0.46) | CRHR1SLC6A2 | |
| SCHEMBL5865728 | 0.80 | KMT2A (0.51) | CRHR1 | |
| SCHEMBL17047670 | 0.77 | S100B (0.44) | — | |
| SCHEMBL5865767 | 0.76 | CRHR1 (0.38) | CRHR1HPGDSLC6A4SLC6A2 | |
| SCHEMBL6574108 | 0.76 | CRHR1 (0.33) | CRHR1 | |
| SCHEMBL28512003 | 0.75 | CYP3A4 (0.33) | CRHR1HPGDSLC6A4SLC6A2 | |
| SCHEMBL9424150 | 0.75 | KMT2A (0.38) | CRHR1HPGD | |
| SCHEMBL6571582 | 0.75 | GAA (0.40) | CRHR1 | |
| SCHEMBL17047623 | 0.75 | ALDH1A1 (0.41) | CRHR1 | |
| SCHEMBL6572721 | 0.73 | KDM4E (0.35) | CRHR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056925-B2 | for example, N-{2-[benzyl(2-hydroxyethyl)amino]-5-bromophenyl)}-N'-(5-cyano-2-pyrazinyl)urea, N-{5-bromo-2-[(2-hydroxy-2-phenylethyl)(methyl)amino]phenyl}-N'-(5-cyano-2-pyrazinyl)urea; anticarcinogenic agents | ABBOTT LABORATORIES (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1534692-A1 | UREA DERIVATIVES AS KINASE INHIBITORS | Abbott Laboratories (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040259885-A1 | Urea kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
| WO-2004014876-A1 | UREA DERIVATIVES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20040034038-A1 | Urea kinase inhibitors | ABBOTT LABORATORIES | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034038-A1 | Urea kinase inhibitors | UCK2, CMPK1, CDK2 | CRHR1 4751/4885HPGD 1552/4885SLC6A4 4730/4885 |
| US-20040259885-A1 | Urea kinase inhibitors | UCK2, CMPK1, CDK2 | CRHR1 4751/4885HPGD 1552/4885SLC6A4 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.